الفهرس 
oooooooOnly 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
Since ancient times, plants have been an exemplary source of medicine. The use of plants in treatment of various human ailments. About several thousands plants have been claimed to possess medicinal properties.
Traditional medicine derived from medicinal plants is used by about 60% of the world’s population. Fenugreek has a long history of medical uses in Egypt medicine, and has been used for numerous indications, including labor induction, aiding digestion, and as a general tonic to improve metabolism and health. Preliminary animal and human trials suggest possible hypoglycemic and antihyperlipidemic properties of oral fenugreek seed powder. where the main chemical constituents are flavonoids, saponins, polysaccharides, vitamin A, tannic acids, fixed and volatile oils and a bitter principles, diosgenin, alkaloids such as trigonelline, and the major free amino acid 4-hydroxyisoluceine (4-OH-lle), which has been characterized as one of the active ingredients in fenugreek for blood glucose control.
Purpose: To determine bioactivity of fenugreek seed powder (FSP) on diabetic rats (12 weeks) after diabetes induction. Methods: 50 albino wistar rats weighing 120-180 g were divided into 2 main groups: Group (1) normal rats (10 rats) and group (2) contain (40 rats) were injected by alloxan monohyderate in a dose of 130 mg/kg of b. wt. intraperitoneally (i.p.) for seven days. Glycemia and glucosurea were determined before induction, rats are becoming diabetics after seven days after alloxan injection rats were became diabetics. Treatment for groups started after diabetes induction. Diabetic rats were divided into four subgroups as following: Subgroup (1) diabetic rats as positive control (10 rats). Subgroup (2) diabetic treated with FSP by a dose of 5% FSP daily mixed in diet (10 rats), subgroup (3) diabetic group treated with rosiglitazone which suspended in Carboxy Methyl Cellulose (CMC) 1% by a dose of 5 mg/kg body weight/day orally dose by stomach tube, and subgroup (4) diabetic group treated with metformin HCl by a dose of 350 mg/kg/day body weight orally by stomach tube.
Results: The assessment of blood glucose level showed that reduction of blood glucose level in all treated groups (FSP, rosiglitazone and metformin) compared to diabetic group, also kidney function test (blood urea and serum creatinine) were determined and recorded that kidney functions were improved in all treated groups (FSP, rosiglitazone and metformin) compared by diabetic group. By determination of lipid profile (cholesterol, triglycerides, HDL-Ch, LDL-Ch) found that FSP has lowering effects for cholesterol, triglycerides, LDL-Ch and increasing in HDL level compared to diabetic group.
Determination of Malondialdehyde in kidney tissues observed that MDA level increased in diabetic rats while reduced in all treated groups.
Assessment of antioxidant enzyme:
1- Glutathione: Significant rising of GSH levels in FSP, rosiglitazones and metformin treated groups compared to diabetic group.
2- Superoxide dismutase: Significant rising of SOD enzyme levels in FSP, rosiglitazones and metformin treated groups compared to diabetic group diabetic group.
3- Catalase enzyme: Significant rising in Catalase enzyme levels in FSP rosiglitazones and metformin treated groups compared to diabetic group diabetic group.
Determination of IL-6 in kidney tissues observed that IL-6 level increased in diabetic rats and after the treatment period found that reduction in its levels in FSP, Rosiglitazone and metformin treated groups.